Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
出版年份 2013 全文链接
标题
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
作者
关键词
-
出版物
BLOOD
Volume 122, Issue 4, Pages 515-522
出版商
American Society of Hematology
发表日期
2013-05-24
DOI
10.1182/blood-2013-02-483750
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
- (2012) S. Branford et al. BLOOD
- Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
- (2012) M. Tang et al. HAEMATOLOGICA
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
- (2012) Ho-Young Yhim et al. LEUKEMIA RESEARCH
- Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
- (2011) D. M. Ross et al. HAEMATOLOGICA
- Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
- (2011) N. Takahashi et al. HAEMATOLOGICA
- Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
- (2011) Jan Krönke et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
- (2011) Hyun-Gyung Goh et al. LEUKEMIA & LYMPHOMA
- In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
- (2010) M. Sobrinho-Simoes et al. BLOOD
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
- (2010) D M Ross et al. LEUKEMIA
- Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
- (2009) T. Lenaerts et al. HAEMATOLOGICA
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
- (2008) Dushyant Verma et al. LEUKEMIA & LYMPHOMA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started